ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nilotinib

Also written as “Nilotinib”, “AMN107” and “Tasigna”.

Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Gastrointestinal Stromal Tumors · Neoplasms · Leukemia, Myeloid, Chronic-Phase · Leukemia, led by 3 companies.

Drug pageNilotinib: every studyAll 134 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 19, 200857 company-led studies, 1 open or runningNext primary completion: Aug 30, 2030 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only541 open or runningphase 4since Sep 19, 2008May 2, 2005Aug 30, 2030phase 4 · NCT04877522
Xspray Pharma AB20 open or runningphase 1since Jul 29, 2025Jul 29, 2025none ahead
XSpray Microparticlesits history only10 open or runningphase 1since Feb 19, 2014Feb 19, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Xspray Pharma AB only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 29, 2025First studies: 2 phase 1 studies in NeoplasmsFirst studyNCT07138378, NCT07138352

TargetBeta

ABL1 →BCR →read by rule
“Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
asciminibruleNovartisphase 416
olverembatinibruleAscentage Pharma Group Internationalphase 310
EmbibatinibHansoh Pharmaceutical Groupphase 37
TQB3911Sino Biopharmaceuticalphase 11

Studies

All 2 Xspray Pharma AB leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07138378Neoplasms · India1CompletedDec 15, 2024128
NCT07138352Neoplasms · United States1CompletedJan 8, 202548

How it is read

Names in the registry

  • “Nilotinib”, 35 entries
  • “nilotinib”, 9 entries
  • “AMN107”, 3 entries
  • “Tasigna”, 2 entries
  • “Nilotinib (AMN107)”, 2 entries

Codes read as this program: XS003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.